Summary Resistance of tumour-bearing mice to a second tumour challenge, that is concomitant resistance, was evaluated in euthymic and nude mice using nine tumours with widely different degrees of immunogenicity. Two temporally separate peaks of concomitant resistance were detected during tumour development. The first one was exhibited only by small immunogenic tumours; it was tumour specific and mediated by classical immunological T-cell-dependent mechanisms. The second peak was shared by both immunogenic and nonimmunogenic large tumours; it was non-specific, thymus independent and correlated with the activity of a serum factor (neither antibody nor complement) that inhibited the in vitro proliferation of tumour cells. This factor was eluted from a Sephadex G-15 column at fractions corresponding to a molecular weight of approximately 1000 Da and it was recovered from a high-performance liquid chromatography column in one peak presenting maximum absorption at 215 and 266 nm. The data presented in this paper suggest for the first time, to our knowledge, that in spite of the differences between immunogenic and non-immunogenic tumours, a common serum-mediated mechanism seems to underlie the concomitant resistance induced by both types of tumours at late stages of tumour development.
Concomitant resistance is the phenomenon according to which a tumour-bearing host inhibits the growth of a secondary implant of the same tumour at a distant site. It can be induced by both immunogenic and non-immunogenic tumours but the mechanisms involved have been reported to be different. In effect, concomitant resistance induced by strongly immunogenic tumours has been described as tumour specific and mainly mediated by T-cell-dependent cytotoxic mechanisms, not different from a classical immunological rejection (Belehradek et al., 1972; Chandradasa, 1973; Tuttle et al., 1983; North, 1984; Akporiaye et al., 1988) . On the other hand, concomitant resistance induced by weakly or non-immunogenic tumours has been described as non-specific and mediated by a cytostatic mechanism presumably unrelated to any known conventional immunological mechanism (Gorelik et al., 1981; Gorelik, 1983; Ruggiero et al., 1985; Meiss et al., 1986; Bonfil et al., 1988) . In a former paper (Ruggiero et al., 1990) we demonstrated that the serum from mice bearing non-immunogenic tumours exhibited a growth-inhibitory activity (not attributable to cytotoxic antibodies) on in vitro proliferation of tumour cells that was proportional to the intensity of concomitant resistance.
As a continuation of our previous papers, the aim of this study was to determine whether immunogenic tumours could also induce a form of concomitant resistance similar to that demonstrated for non-immunogenic tumours.
Materials and Methods Animals BALB/c mice of both sexes, 2-4 months old, were used throughout. They were raised in our own colony and maintained on Nutric pellets (Cordoba) and water ad libitum. Nude BALB/c mice of both sexes, 2-4 months old were obtained from the Comision Nacional de Energia Atomica, Argentina, and kept under relatively aseptic conditions. Parabiotic BALB/c mice were prepared by joining pairs of BALB/c mice, 2-3 months old, in parabiotic union involving the skin and peritoneal cavities; crosscirculation is established around day 7 according to our previous experience. Animals were age and sex matched within each experiment. Tumours MC-B: fibrosarcoma induced in a 4-month-old BALB/c male, 2.5 months after the s.c. implantation of methylcholanthrene crystals. It was used between s.c. passages 6 and 23. MC-C: fibrosarcoma induced in a 5-month-old BALB/c male 3 months after the s.c. implantation of a methylcholanthrene pellet. It was used between s.c. passages 5 and 20. MC-D: fibrosarcoma induced in a 6-month-old BALB/c male, 4 months after the implantation of a methylcholanthrene pellet. It was used between s.c. passages 6 and 17.
M3: mammary adenocarcinoma that arose spontaneously in a BALB/c female and maintained by s.c. syngeneic passages. It was used between passages 61 and 71. More detailed description of this tumour is given elsewhere (Klein et al., 1980) . transplantation. It was used between passages 18 and 42.
More detailed description of this tumour is given elsewhere (Bonfil et al., 1989; Kordon et al., 1991 , 1951) . Detailed description of the preparation of the a.e. of L15 and the rationale of this procedure in order to permit allogeneic tumour growth are given elsewhere (Pasqualini et al., 1976; Rao and Bonavida, 1976) .
LB: T-lymphoid leukaemia that arose spontaneously in a 6-month-old BALB/c male. It was maintained by s.c. serial passages in syngeneic mice and was used between passages 69 and 170. More detailed description of this tumour is given elsewhere (Ruggiero et al., 1985; Zahalka et al., 1993) .
All tumours were kept biofrozen and were thawed and s.c. passaged.
TD50 is defined as the number of tumour cells able to grow s.c. in 50% of the mice.
Immunisation assays Tumour implantation and excision Subcutaneous tumours were surgically excised when their volume had reached 400-600 mm3; 2 weeks later, tumour challenge was carried out in the contralateral flank of the mice that had not relapsed.
Sublethal doses Mice that had survived a first tumour implant were reinoculated with various doses of the same tumour.
Irradiated cells Cell suspensions were irradiated with 90 Gy in a plastic irradiation chamber; X-rays were generated in a Philips 250/15 Radiotherapy apparatus at 220 kV, 14 mA, and filtered with 1 mm Al. The dose rate was 3.15 Gy min-I at a focus -target distance of 29 cm. Animals were pretreated with two s.c. doses of 2-4 x 106 irradiated tumour cells, 7 and 14 days before tumour challenge.
Concomitant resistance assay Mice received a s.c. tumour implant in the right flank followed, at different intervals, by a second s.c. implant of the same tumour in the left flank. Control mice were challenged only in the left flank. The titre of concomitant resistance was defined as the ratio between TD50 of the second challenge in tumourbearing mice and TD50 in control mice, and expressed as a function of the primary tumour volume at the day of the second challenge.
Tumour volume was calculated according to the formula of Attia and Weiss (1966); volume = 0.4 (a b2), where a and b are the larger and smaller diameters respectively.
Serum
Normal and tumour-bearing mice were bled through the retro-orbital plexus. The blood was kept at room temperature for 1 h for clotting. Serum obtained after centrifugation was stored at -20°C until used. For in vitro assays, serum was decomplemented at 56°C for 30 min.
Medium
The medium used was RPMI-1640 (Gibco, Grand Island, NY, USA), with penicillin G sodium (10Ig ml-1), streptomycin sulphate (25 ug ml-') and amphotericin B as fungizone (25 jug ml-'). Medium was supplemented with 5% fetal calf serum. 
Results
Immunogenicity of nine murine tumours Immunogenicity of nine murine tumours was studied in BALB/c mice using three immunisation assays: tumour implantation and excision, pretreatment with tumour irradiated cells and pretreatment with tumour sublethal doses. Similar results were obtained with the three immunisation procedures and therefore their data were pooled. Results are shown in Table I , where the increase in TD50 after the immunisation procedures was taken as a Figure 1 , two peaks of concomitant resistance could be detected during tumour development: the first peak was observed when the primary tumour was small at the moment of the second challenge; it seemed to be thymus dependent as it was present in euthymic but not in nude mice, and it was proportional to tumour immunogenicity (P <0.0001, Spearman correlation), that is, the more immunogenic the tumour, the higher the first peak of concomitant resistance; reciprocally, when tumour immunogenicity was weak (M3 tumour) or absent (LB and C7HI tumours), the first peak did not appear. On the other hand, the second peak was observed late during tumour development, that is, when the primary tumour was large; it seemed to be thymus independent as it was present in both euthymic and nude mice, and it did not correlate with tumour immunogenicity (P=NS, Spearman correlation); for example, similar high values in the second peak of concomitant resistance were obtained with L15 and LB in spite of sharp differences in their tumour immunogenicity; reciprocally, sharp differences in the second peak were seen with LB as compared with C7HI in spite of their lacking any detectable immunogenicity. It is noteworthy that the only tumour that did not show concomitant resistance at any stage of tumour development was the highly metastatic C7HI. Figure 1 also reveals that between the first and the second peak, concomitant resistance was weak or absent, with the only exception being the L15 tumour, where it remained at a high level throughout tumour development.
Histological studies have shown differences between the first and the second peak of concomitant resistance. In effect, histological examination of skin at the site of a 9 day MC-C secondary implant revealed a profuse infiltration with host cells (macrophages, polymorphonuclear granulocytes and lymphocytes) if the second challenge was performed when primary MC-C tumour was small. By contrast, no signs of a conventional immunological rejection, with morphologically well-preserved tumour cells, accompanied the growth inhibition of the second tumour challenge if it was carried out when the primary tumour was large. Similarly, lack of cellular infiltration and a well-preserved state of secondary tumour cells were observed in mice bearing the nonimmunogenic LB tumour at late stages of tumour develop- Table II , concomitant resistance against a second implant with a different tumour could only be observed when the primary tumour was large at the time of the second implant. These observations suggest that the first peak of concomitant resistance induced by strongly immunogenic tumours (see Figure 1 ) was specific but the second peak, shared by large tumours independently of their immunogenicity, had some degree of non-specificity. Afterwards, when tumour size increased, this cytotoxic activity soon disappeared in mice bearing MC-C tumour whereas it slowly decayed but did not disappear, in mice bearing L15 tumour. No in vitro anti-tumour cytotoxic activity was ever detected when spleen cells from tumourbearing nude mice were used (data not shown).
Similar results were obtained when anti-tumour immunity was tested using two in vivo assays: the adoptive transference and the Winn test. In effect, as shown in Table III In order to test natural killer (NK) activity, spleen cells from MC-C-bearing mice were in vitro assayed against 51Cr-labelled YAC-1 cells. In tumour-bearing euthymic mice, NK activity was lower than normal at every stage of tumour growth. In tumour-bearing nude mice, NK values higher than normal were seen when MC-C was small; when MC-C was larger NK activity gradually decreased to normal values (data not shown). Inhibitory activity in serum of tumour-bearing hosts against tumour cells in vitro Serum collected from tumour-bearing BALB/c mice exhibited, in a [3H]thymidine uptake assay, an inhibitory activity on in vitro proliferation of the same tumour cells. Serum was routinely decomplemented before use (when non-decomplemented serum was used, similar results were obtained). As can be seen in Figure 3 , this activity was proportional to Tumour volume (mm3) Table IV . This inhibitory activity correlated with the intensity of the second peak of concomitant resistance (P< 0.02, Spearman correlation); that is, the higher the second peak of concomitant resistance, the stronger the inhibitory activity found in the serum of tumour-bearing mice; for example, LB-bearing mice exhibited the highest second peak of concomitant resistance (see Figure 1 ) and (Figure 3 ) strongly contrasts with the absence of cytotoxic antibodies as evaluated by the 51Cr release assay in the same sera ( Figure   2 ). Furthermore, sera from mice that had been immunised against L15 (but not bearing the tumour) exhibiting a high titre of cytotoxic antibodies (Figure 2 ), did not show any inhibitory activity on in vitro tumour proliferation (data not shown). Similar results to those obtained in euthymic mice were registered in nude mice (Figure 3) , suggesting that this inhibitory activity is thymus independent. against MC-C (mean + s.e. of three experiments) was 202.9+12.1 GIU50 ml-1 (ratio to normal serum: 4.4; P<0.01) and against LB (mean+s.e. of three experiments) was 161.7+33.7 GIU50 ml-' (ratio to normal serum: 3.1; P<0.05). The non-specific in vitro inhibition of LB tumour cell proliferation by serum from mice bearing a large MC-C tumour paralleled the non-specific in vivo inhibition of a second implant of LB in mice bearing a large MC-C tumour (see Table II ).
Physical properties and serum fractionation Serum from mice bearing an MC-C tumour > 2000 mm3 was subjected to dialysis (12 500 molecular weight cut-off Figure 5) . ime (min) Previous studies using non-immunogenic tumours have described the existence of concomitant resistance at late stages of tumour growth (here referred to as second peak of concomitant resistance) and a serum-mediated mechanism was suggested (Ruggiero et al.. 1990 : Prehn. 1993 ). On the contrary. most of the authors studying concomitant resistance induced by strongly immunogenic tumours have described the existence of the first peak but not that of the second peak of concomitant resistance (Belehradek et al.. 1972 : Chandradasa, 1973 Vaage, 1973 : Howell et al.. 1975 : Berendt et al., 1978 : Leveson et al., 1979 : Finlay-Jones et al.. 1980 : Tuttle et al.. 1983 . There are three possible explanations for this. First, many of these studies were restricted to relatively early stages of tumour development (Belehradek et al.. 1972; Chandradasa, 1973; Vaage. 1973 : Howell et al., 1975 : Berendt et al.. 1978 Leveson et al.. 1979 : Finlay-Jones et al.. 1980 . Second, the evaluation of concomitant resistance was often not completely adequate:
in effect, most of those studies were carried out using only one dose of tumour cells as the second challenge (Vaage. 1973: Howell et al.. 1975 : Berendt et al.. 1978 Leveson et al.. 1979 : Finlay-Jones. 1980 ). Third. in some experiments. concomitant resistance could not be strictly tested as the primary tumour was excised soon after the second challenge (Vaage. 1973 (Vaage. . 1977 . Our results, describing two temporally separate peaks of concomitant resistance. may explain apparently contradictory results reported by different authors: for example. both Berendt et al. (1978) and Gorelik (1983) have worked with the same tumour, the strongly immunogenic Meth A. using similar tumour doses for the first and the second challenges: however, whereas Berendt et al. stated that resistance to a second Meth A tumour challenge was observed transiently in mice bearing a very small Meth A tumour. Gorelik stated that resistance to a second Meth A tumour challenge did not appear when the primary tumour was small while its intensity was progressively higher as the primary tumour became larger. In our opinion, the reason for these seemingly contradictory conclusions resides in the different stages of primary tumour growth at which each of these authors has looked for concomitant resistance. Other examples of apparently contradictory but in fact, in our opinion, complementary results. are found in papers studying concomitant resistance associated with melanoma B16 (Leveson, 1979 : Gorelik et al.. 1981 , murine lung Lewis carcinoma 3LL (De Wys. 1972 : Gorelik, 1981 , rat carcinoma of Flexner-Jobling (Woglom. 1929) . methylcholanthrene-induced fibrosarcomas (Deckers et al.. 1973; Kearney and Nelson, 1973; Nomi et al., 1986 ).
In conclusion, the data presented in this paper suggest for the first time, to our knowledge, that besides the classical immunological mechanism of concomitant resistance induced by small immunogenic tumours, a common mechanism. mediated by serum factors of low molecular weight. seems to underlie the concomitant resistance induced by both immunogenic and non-immunogenic tumours at late stages of primary tumour development.
